Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
2005年6月23日 更新者:Glaxo Wellcome
A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg Once Daily Vs. Lamivudine 150mg BID in Combination With Zidovudine 300mg BID and Efavirenz 600mg Once Daily in Antiretroviral-Naive Adults With HIV-1 Infection
The purpose of this study is to look at the safety and effectiveness of receiving lamivudine (3TC) once a day versus twice a day as part of an anti-HIV drug combination.
研究概览
详细说明
Patients are randomized to receive the same total dosage of 3TC either twice a day (Group 1) or once a day (Group 2) in combination with ZDV and EFV over 48 weeks.
Viral load measurements will be performed at Weeks 4, 8, 12, 16, 20, 24, and every 8 weeks thereafter.
研究类型
介入性
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大
- Southern Alberta HIV Clinic / Foothills Hosp
-
-
British Columbia
-
Vancouver、British Columbia、加拿大
- Saint Paul's Hosp
-
-
Ontario
-
Toronto、Ontario、加拿大
- Sunnybrook Health Science Centre
-
Toronto、Ontario、加拿大
- Toronto Gen Hosp
-
Toronto、Ontario、加拿大
- Wellesley/Central Site / St Michael's Hospital
-
-
Quebec
-
Montreal、Quebec、加拿大
- Clinique Medicale du Quartier Latin
-
Montreal、Quebec、加拿大
- Clinique Medicale L'Actuele
-
Ste Foy、Quebec、加拿大
- Centre Hospitalier Universitaire de Quebec
-
-
-
-
-
Campinas - SP、巴西
- Universidade de Campinas
-
Manguinhos RJ、巴西
- Hosp Evandro Chagas Fioernz
-
Rio de Janeiro - RJ、巴西
- Hosp Univ Clementino Fraga Filho
-
Rio de Janeiro - RJ、巴西
- Hosp Univ Pedro Ernesto / Univ Estadual do RJ
-
Sao Paulo - SP、巴西
- Hosp Sao Paulo da Universidade Federal de Sao Paulo
-
-
-
-
-
Caguas、波多黎各、00726
- Caguas Regional Hosp
-
Cotto Laurel、波多黎各、00780
- Hosp San Cristobal-Edif A
-
Guaynabo、波多黎各、00966
- Carlos Leon-Valiente MD
-
Mayaguez、波多黎各、00680
- Ramon Ramirez Ronda MD
-
Santurce、波多黎各、00908
- San Juan AIDS Program
-
-
-
-
Arizona
-
Phoenix、Arizona、美国、85016
- Phoenix Body Positive
-
-
California
-
Beverly Hills、California、美国、90211
- Pacific Oaks Research
-
Los Angeles、California、美国、90048
- Tower ID Med Associates
-
Los Angeles、California、美国、900276069
- Aids Healthcare Foundation
-
San Francisco、California、美国、94118
- Kaiser Foundation Hospital
-
San Francisco、California、美国、94114
- Davies Med Ctr / c/o HIV Institute
-
Torrance、California、美国、90509
- Harbor - UCLA Med Ctr
-
-
District of Columbia
-
Washington、District of Columbia、美国、20037
- George Washington Univ Med Ctr
-
Washington、District of Columbia、美国、20007
- Georgetown Univ Med Ctr
-
-
Florida
-
Altamonte Springs、Florida、美国、32701
- IDC Research Initiative
-
Bradenton、Florida、美国、34205
- Bach and Godofsky
-
Fort Lauderdale、Florida、美国、33308
- TheraFirst Med Ctrs Inc
-
Fort Lauderdale、Florida、美国、33316
- North Broward Hosp District
-
Fort Lauderdale、Florida、美国、33334
- The Coleman Institute Inc
-
Fort Pierce、Florida、美国、34950
- The Coleman Institute Inc
-
-
Georgia
-
Atlanta、Georgia、美国、30339
- Kaiser Permanente Infectious Diseases
-
-
Illinois
-
Chicago、Illinois、美国、60657
- AIDS Research Alliance - Chicago
-
-
Indiana
-
Indianapolis、Indiana、美国、46218
- Infectious Disease of Indiana
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- Univ of Kentucky Med Ctr
-
-
Louisiana
-
New Orleans、Louisiana、美国、70112
- Tulane Univ School of Medicine
-
-
Massachusetts
-
Boston、Massachusetts、美国、021182393
- Boston Med Ctr / Evans - 556
-
-
Missouri
-
Kansas City、Missouri、美国、64132
- Antibiotic Research Associates
-
-
New Jersey
-
East Orange、New Jersey、美国、07018
- East Orange Veterans Administration Med Ctr
-
New Brunswick、New Jersey、美国、08901
- ID Care Inc
-
Princeton、New Jersey、美国、08540
- ID Care Inc
-
Randolph、New Jersey、美国、07869
- ID Care Inc
-
Somerville、New Jersey、美国、08876
- ID Care Inc
-
-
New York
-
Albany、New York、美国、12208
- Albany Med College / Div of HIV Medicine
-
Manhasset、New York、美国、11030
- North Shore Univ Hosp / Div of Infectious Diseases
-
New York、New York、美国、10011
- St Vincents Hosp / Clinical Research Program
-
New York、New York、美国、10019
- St Lukes / Roosevelt Hosp / HIV Center
-
-
Ohio
-
Columbus、Ohio、美国、432101228
- Ohio State Univ Hosp Clinic
-
-
Oklahoma
-
Tulsa、Oklahoma、美国、74107
- Oklahoma State University / College of Osteopathic Medicine
-
Tulsa、Oklahoma、美国、74114
- Associates in Med and Mental Health
-
-
Rhode Island
-
Providence、Rhode Island、美国、02906
- Miriam Hosp / Brown Univ
-
-
Tennessee
-
Memphis、Tennessee、美国、38104
- Methodist Healthcare
-
Memphis、Tennessee、美国、38163
- Univ of Tennessee
-
Nashville、Tennessee、美国、37203
- Vanderbilt Univ Med Ctr
-
-
Texas
-
Dallas、Texas、美国、75219
- Nelson-Tebedo Community Clinic
-
Dallas、Texas、美国、75219
- Dr David Donnell
-
Galveston、Texas、美国、77555
- Univ of Texas Med Branch
-
Houston、Texas、美国、77006
- Montrose Clinic
-
Houston、Texas、美国、770303498
- Baylor College of Medicine / Dept of Medicine
-
Houston、Texas、美国、77030
- Univ of Texas / Med School at Houston
-
San Antonio、Texas、美国、782847838
- Univ of Texas Health Sciences Ctr
-
-
Virginia
-
Hampton、Virginia、美国、23666
- Hampton Roads Med Specialists
-
-
-
-
-
Buenos Aires、阿根廷
- Hosp Muniz
-
Rosario - Santa Fe、阿根廷
- CAICI
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria
Patients may be eligible for this study if they:
- Are 18 years of age or older.
- Are HIV-positive.
- Have a viral load (level of HIV in the blood) of at least 400 copies/ml within 21 days of study entry.
- Have a CD4 count greater than 100 cells/mm3 within 21 days of study entry.
- Agree to practice abstinence or use effective barrier methods of birth control (or, if patient is a woman, unable to have children).
Exclusion Criteria
Patients will not be eligible for this study if they:
- Have taken any antiretroviral (anti-HIV) agent.
- Are pregnant or breast-feeding.
- Are unable to absorb food or have trouble taking medicines by mouth.
- Abuse alcohol or drugs to an extent that may make study participation difficult.
- Are not likely to be able to complete the 48 weeks of study treatment.
- Have a history of pancreatitis (inflamed pancreas) or hepatitis within the last 6 months or any evidence of liver disease.
- Have received an investigational vaccine within the past 3 months or have received gene therapy.
- Have a severe medical condition such as diabetes or heart trouble.
- Have been diagnosed with AIDS.
- Have had radiation therapy or chemotherapy within 30 days of study entry, except for treatment of Kaposi's sarcoma.
- Are taking medications that affect the immune system within 30 days of study entry.
- Are taking medications that may interact with the study drugs.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 屏蔽:双倍的
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
1999年9月1日
研究注册日期
首次提交
2000年3月2日
首先提交符合 QC 标准的
2001年8月30日
首次发布 (估计)
2001年8月31日
研究记录更新
最后更新发布 (估计)
2005年6月24日
上次提交的符合 QC 标准的更新
2005年6月23日
最后验证
2000年8月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 225D
- EPV2000 1
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.